Wednesday, 24 June 2020

Fungal Endocarditis Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

Market Scenario
Fungal endocarditis is a rare and extremely enfeebling disease associated with high rate of mortality of around 50%. The condition is usually being diagnosed postmortem. The etiologic fungi more commonly observed are the Candida and Aspergillus species.
As per the study published in the International Cardiovascular Research Journal in 2014, it is found that Candida albicans, and Aspergillus species are the most frequent cause of fungal endocarditis. Candida albicans is found to be responsible for 24%-46% of cases of fungal endocarditis, and for 3.4% of the prosthetic valve endocarditis cases with associated mortality rates of 46.6%-50%. After Candida, Aspergillus species is the second most common cause of fungal endocarditis, accounting for nearly 25% of the cases of fungal endocarditis in cardiac valve prostheses and the great vessels.
With an increasing age, the incidence of Candida fungal endocarditis decreases whereas the incidence of Aspergillus fungal endocarditis increases. The affected cardiac sites in neonates is significantly different from the adults with the right atrium being predominant in 63% of neonates
The possible complications associated with fungal endocarditis are congestive heart failure, mitral and aortic valve incompetence, neurological complications, formation of myocardial abscesses, and metastatic infections. According to a study published in PLOS one in 2013, it is found that the incidence of hospitalization for fungal endocarditis in the United States is 12.7 per 100,000 annually.
Notably, rising awareness about fungal infections is the key factor driving the fungal endocarditis market. Nowadays, people are becoming more aware about the different types of fungal infections. Government and other different organizations have started educating people about the hygiene and infectious diseases. People are becoming more aware and conscious about the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other push factors such as increasing incidents of fungal infections, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global fungal endocarditis market.
Despite these drivers, there are some issues associated with fungal endocarditis market. Some of the challenges in research and development are side-effects of treatment, presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, which may hinder the growth of the market to an extent. In contrast to the remedial effects, antifungal treatment can have many side effects as well. Some of them include: irritation, itching, headache, diarrhoea, and anaemia. They are also responsible for causing kidney and liver damage. Beside this, many antifungal medicines can cause allergic reactions, thus, they are not prescribed to pregnant women and children.
It is estimated that the fungal endocarditis market is expected to grow at a CAGR 4.2% during the forecast period of 2017-2023.
Intended Audience
  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institute
  • Academic Institutes and Universities
Segmentation
The global fungal endocarditis market is segmented on the basis of type of causative agent, diagnosis, treatment, and end-user.
On the basis of the type of causative agent, the market is segmented into Candida species
Aspergillus species, and Histoplasma capsulatum.
On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram
On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.
On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the fungal endocarditis market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the fungal endocarditis market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
The Asia Pacific is the fastest growing fungal endocarditis market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the global fungal endocarditis market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, and Others. 
Posted by at No comments:

Global Neuropathology Market 2019 To 2023 Professional Overview, Detail Analysis, Growth And Top Key Players Demand

Market Scenario
Neuropathology pertains to the aliment of nerves reculting in pain and numbness of the limbs and it is gaining prominence in this market. The increasing incidence of musculoskeletal conditions and technological advancements in medical diagnostic devices are some factors responsible for the growth of the global neuropathology market.
The work of the neuropathologists includes examining biopsy tissue from the brain and spinal cord to diagnose a disease. The biopsy is usually performed if a mass is detected by radiologic imaging. In case of autopsies, the foremost work of the neuropathologist is to help in the post-mortem diagnosis of various forms of neural conditions such as dementia and other, that may have affected the central nervous system.
The number of patients suffering from cerebrovascular disorders has increased rapidly and has reached an all-time high in the past few years. There has been a significant rise in the number of surgeries associated with the treatment of such disorders. As the neurosurgeries and spinal surgeries are very critical, continuous monitoring during the whole procedure proves to be beneficial as the information about the electrical signals in brain and the nerves can be obtained in real time.
Biopsies primarily consist of the skin. The recently developed neuropathy test, the epidermal nerve fiber density testing (ENFD) in which the nerve fibers of the skin is analysed by performing a  punch skin biopsy to identify small fiber neuropathies. This pathology test is becoming available in selected labs as well as a few universities; it replaces the traditional sural nerve biopsy test and is less invasive. It is used to identify painful small fiber neuropathies.
There are many neuropathologists around the world who have made important clinical and research contributions toward our understanding of diseases that specifically affect the brain (degenerative diseases, multiple sclerosis, stroke, brain tumors, trauma and neuromuscular diseases). A majority of them are members of the International Society of Neuropathology (ISN).
The diagnostic samples comprises of aspirates and bone-marrow biopsies, lymph-node biopsies, body fluids, peripheral blood smears, and tissue resections from various CUMC units. Morphologic evaluation and studies, including flow cytometry, immunohistochemistry, next-generation sequencing and cytogenetic analysis are performed in diagnostic laboratories.
The laboratory also analyses biopsies using histochemical and immunohistochemical methods to identify glycogenosis, lipid storage myopathy, mitochondrial myopathy, muscular dystrophy, and their inherited disorders. In appropriate cases, further biochemical and genetic analysis of muscle is performed by Laboratory of Personalized Genomic Medicine at CUMC.
According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases. Many healthcare professionals have started using these diagnostics techniques, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for Neuropathology.
The Global Neuropathology market is expected to grow at a CAGR of approximately 6% during the forecast period 2017-2023.
Intended Audience
  • Neuropathology Suppliers
  • Neuropathology Manufacturers
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities
Segmentation
The Neuropathology is segmented on the basis of diagnosis test, application, and end-users.
On the basis of diagnostic test, the market is segmented into the biopsy, body fluids, peripheral blood smears, tissue resections, and others 
The biopsy sub-segment is divided into Epidermal nerve fiber density testing (ENFD), Sural nerve biopsy test, bone-marrow biopsies, lymph-node biopsies and others
On the basis of product, the application market is segmented into cerebral hypoxia and stroke, perinatal disorders, CNS infections, demyelinative diseases, brain tumors, neurodegenerative diseases, inherited metabolic disorders, peripheral neuropathy, and myopathology
On the basis of end-user, the market is segmented into hospitals, clinics, research centers and others.
Regional Analysis
The Global Neuropathology Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global neuropathology market owing to the increasing healthcare expenditure in North America since 2016. U.S. has some of the best hospitals in the world with state of the art infrastructure. Most of the hospitals and their neurology departments are well equipped with the equipment that is required for the working of the neuropathology techniques. Various organizations and private companies are engaged in the activities of spreading awareness about the benefits of the neuropathology test among common people through various educational and marketing ways. As a result, huge numbers of people are opting for the neuropathology tests as a point of care. The country has been developing number of academic courses to develop skilled personnel in the neuropathology field over the years. Hence the availability of the neuropathology specialists in North American countries is high.
Europe is the second largest market for neuropathology market. For Europe, the neuropathology market including the brain tumors market is regarded as a strong competitive market. European countries are now making efforts in promoting the benefits of the intraoperative neurophysiological monitoring services. Patient friendly healthcare and insurance policies are making a positive impact on the people taking medical assistance.
Asia Pacific is the fastest growing region over the forecast period. The healthcare spending in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Key Players
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.
Some of key the players in the Global Neuropathology Market are ARUP Laboratories, Therapath LLC, Abbott Laboratories, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Sakura Finetek USA Inc., Danaher Corporation, Quest Diagnostics Incorporated, Agilent Technologies Inc., and NeoGenomics Laboratories and others.
Posted by at No comments:

Augmented Bone Graft Market Financial Overview, Swot Analysis, Key Development And Forecasts Till 2023

According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.
The Global Augmented Bone Graft Market is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.
Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.
There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.
Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.
Additionally, stringent regulations obstruct the growth of augmented bone grafts market size and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.
The Key Players
  • Zimmer Holdings, Inc.
  • BioMimetic Therapeutics LLC
  • Wright Medical Technology, Inc.
  • Stryker Corporation, Smith & Nephew Plc
  • RTI Surgical, Inc.,
  • Olympus Biotech Corporation
  • NuVasive, Inc.
  • NovaBone Products LLC
  • Medtronic, Inc.
  • LifeNet Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • Exactech, Inc.
  • DePuy Spine, Inc.
  • Synthes Inc.
  • DePuy Synthes Companies
  • Biomet, Inc.
Segmentation
The Augmented Bone Graft is segmented on the basis of products, application, and end-users.
On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion
On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.
On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.
Regional Analysis
The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.
For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.
Posted by at No comments:

Retropharyngeal abscess Market Key Manufactures Shares, Analysis And Forecasts Till 2023

Market scenario:
Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.
The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.
The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.
Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.
Key Players
  • Merck KGaA,
  • Johnson & Johnson,
  • AstraZeneca plc,
  • Sanofi S.A.,
  • Pfizer,
  • Mylan N.V,
  • Novartis AG,
  • Teva pharmaceutical company,
  • GlaxoSmithKline plc.
Segments
The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.
Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.
Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
Regional Analysis
Asia Pacific retropharyngeal abscess market size is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.
A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Posted by at No comments:

Worldwide Intussusception Market Top 10 Players Universal Analysis, Industry Demand And 2023 Forecast

Market Scenario
According to the National health statistics, intussusception affects about 1 in every 1,900 children in the US. Its incidence is more common in children between one to five months, peaking at four to nine months of age, and then gradually declines at around 18 months. Intussusception affects boys and girls, with a ratio of approximately 3:1.
The global intussusception market is expected to reach USD 6.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Intussusception, also called bowel obstruction, is a potentially life-threatening condition caused by folding of one part of the intestine into another part, which causes a blockage in the intestine. The blockage hamper the excretion process. Intussusception is dominant in children of age 2 months-2 years. However, adults may also be affected by the intussusception. It commonly occurs where the small and large intestines meet. Additionally, it can occurs due to various causes such as tumors, inflammation, Meckel's diverticulum, duplication, appendix, hyperplasia of Peyer's patches, intestinal surgery, polyps, tumors, inflammation, etc.
It block the blood supply to intestine and causes tissue death. Tissue death can lead to infection, internal bleeding, tearing, damage to the intestines, and peritonitis. The primary symptoms of intussusception include acute abdominal pain, vomiting, nausea, lethargy, blood or mucus in the stools, constipation, etc. The risk factors for intussusception are age, sex, abnormal intestinal formation at birth, a family history, etc.
The market is growing at a very steady pace. Companies are opting various business strategies to capture a reasonable amount of share in the market. Product development represents the best strategy for dominating the market as surgery is the definitive treatment for intussusception market. The advent of minimally invasive treatment and diagnostic techniques such as computed tomography has changed the market landscape for to a large extent. Miniaturization of surgical instruments and development of minimal invasive treatment such as robotic laparoscopy is expected to drive the future market in the developed regions of North America and Europe. The cost of the product will be a decisive factor in the developing regions such as Asia Pacific and, especially, Africa. The growing demand for better minimally invasive surgical procedures is the greatest unmet need of the market.
The developments in the surgery segment, such as minimal invasive laparoscopy surgery, is driving the global intussusception diagnosis and treatment market. The drug segment is, however, suffering from market fragmentation, which has put pressure on the price margins. The loss of patents and the rise of counterfeited drugs has also restricted the market growth. The other market constrains are high cost of surgery and complications of the surgery. Market development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to minimal invasive surgical procedures.
Key Players in the Global Intussusception Market
Some of the key players profiled in the report are Pfizer, Inc., Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, Bayer AG, FUJIFILM Holdings Corporation, General Electric Company, Shimadzu Corporation, Carestream Health, Bristol-Myers Squibb Company, and others.
Segments of Global Intussusception Market
The global intussusception market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on the type, the market has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others.
Based on the surgery, the market has been segmented as surgery, drugs, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Based on the diagnosis, the market has been segmented as barium enema, ultrasound, X-ray, computerized tomography (CT), and others.
Posted by at No comments:

Bronchoscopes Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Market Scenario
Bronchoscopy has become an essential part of modern medicine. The examination by bronchoscopy has become the most common method to diagnose any kind of abnormality in the normal function of the respiratory system. Bronchoscopes are the instruments used for visualizing the insides of the patient’s airways. Bronchoscopes are usually inserted through nose or mouth, and occasionally through the trachea. Owing to the recent advances in medicine, a number of bronchoscopes have been introduced. Flexible bronchoscopes have been introduced to diagnose the diseases in trachea and the bronchi. Due to their different advantages, they are widely accepted throughout various countries and regions. The global bronchoscope industry is majorly driven by increasing prevalence of respiratory tract diseases for instant, lung cancer and COPD, increasing number of bronchoscopies procedures, and increasing preference for minimally invasive procedures.
According to the WHO (World Health Organization), in 2015, 64 million people have chronic obstructive pulmonary disease (COPD), whereas, over 3 million people died of COPD. Additionally 1.8 million people across the globe were suffering from lung cancer. Increasing number of healthcare organization and patient inflow have boosted the number of bronchoscopy procedures. Moreover, increasing geriatric population, increasing healthcare expenditure, and changing environmental condition have fuelled the growth of the market over the review period. However, high cost of the devices and risk of infection may slow the growth of the market.
The bronchoscopes market share is growing at a healthy pace. The market is expected to grow at the CAGR of 7.4% during the forecast period and is estimated to reach USD 2,244.4 million by 2023.
Segmentation                                                                                                                                      
The global bronchoscopes market is segmented on the basis of types, application, and end users.
On the basis of types, the market is segmented into rigid bronchoscopes, and flexible bronchoscopes. Flexible bronchoscopes are further sub-segmented into fiber optic bronchoscopes, and video bronchoscopes.
On the basis of application, the market is segmented into diagnosis, and surgical procedure. Diagnosis is further segmented into examination, patient’s airways, bleeding lungs, possibility of lung cancer, chronic cough, and obtain tissue specimen for biopsy. Surgical procedure is further segmented into removal of a foreign object in the airway, laser resection of tumors, lung abscess, stent insertion, percutaneous tracheostomy, and tracheal intubation.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers and others.
Regional Analysis                     
Considering the global scenario of the market, America dominates the global bronchoscopes market owing to the presence of huge patient population, high healthcare spending and well developed healthcare sector.
North America holds the largest market share in the American bronchoscopes market. According to the Centers for Medicare & Medicaid Services, in 2015, U.S. healthcare spending increased 5.8% during last few years. Additionally, increasing government support for research & development have fueled the market growth of the American bronchoscopes market. Europe has the second largest market for the bronchoscopes which is followed by Asia Pacific. Due to the presence of a well-developed healthcare sector, increasing prevalence of respiratory diseases and high healthcare spending, the bronchoscopes market in Europe is growing at a CAGR of 6.9%. Asia Pacific is also witnessing a rapid growth in this market which is mainly due to rapidly increasing awareness about the availability of the treatment, increasing patient inflow, huge population base, and rising healthcare expenditure. The Middle East & Africa is expected to have limited growth. Middle East is dominating this market by holding major share of the Middle East & Africa market owing to the well developed technology and healthcare sector.
Key Findings:
  • Flexible bronchoscopes segment accounts for the largest market share in the global bronchoscopes market and is expected to be the fastest growing market with the CAGR of 8.0 % during the forecast period.
  • Diagnosis commanded the largest market share in 2016 and was valued at USD 885.7 million in 2016 and is expected to reach at USD 1,484.2 million by 2023.
  • On the basis of end users, Hospitals & clinics segment accounts for the largest market share of 49.1% in the global bronchoscopes market.
  • The Americas bronchoscopes market is expected to reach USD 868.7 million by 2023, at a CAGR of 7.4 % during the forecast period.
Key Players for Global Bronchoscopes Market
Some of the major players in this market are: Ambu Inc. (US), Boston Scientific Corporation (US), Cogentix Medical (US), Fujifilm Holdings Corporation (Japan), Olympus Corporation (Japan), Pentax Medicals (Japan), and KARL STORZ GmbH & Co. KG (Germany), Schindler Endoskopie Technologie Gmbh (Germany), Schölly Fiberoptic Gmbh (Germany), Vimex Sp. (Poland), Hangzhou EndoTop Medi-Tech Co., Ltd.(China), Guangzhou MeCan Medical Limited (China), and LocaMed (UK).
Posted by at No comments:

Eye Care Supplements Market 2019 - Shares, Revenue, Analysis And Forecasts Till 2023

Eye care supplements market growth is expected to show an exponential rate owing to an increasing prevalence of eye diseases and chronic diseases such as diabetes, which are risk factors for eye disease. Furthermore, demand for eye care solutions is increasing across the globe. Therefore, majority of the market players have great opportunities in this market by using strategic approaches such as geographical expansion.
According to the World Health Organization (WHO) estimates, about 285 million people are visually impaired worldwide. According to the Royal National Institute of Blind People (2016), the number of people living with sight loss is expected to reach 2.7 million by 2030 due to possible cases of refractive error, cataract, glaucoma, and others. According to the National Eye Institute, the number of people in the U.S. with cataract is projected to double from 24.5 million in 2010 to 50 million by 2050. Moreover, in 2015, National Eye Institute stated that more than half of the Americans suffer from cataract-related problems in their lifespan.
Segments                                                                                                                                            
The global eye care supplements market is segmented on the basis of type, application, and end user.
On the basis of type, market is segmented into Antioxidant, Fatty acids, anti-inflammatory supplements, neuro-protective supplements and others. Antioxidant segment is further segmented into water -soluble antioxidants including lutein, zeaxanthin, astaxanthin, and fat-soluble antioxidants including astaxanthin. Fatty acids segment is further segmented into omega-6 gamma-linolenic acid. Anti-inflammatory supplements segment is further segmented into docosahexaenoic acid (DHA). Neuro-protective segment is further segmented into eicosapentaenoic acid (EPA).
On the basis of application, the market is segmented into eye health, macular degeneration, cataract, Diabetic retinopathy, glaucoma, and others.
On the basis of end user, the market is segmented into eye hospitals, eye clinics, and others.
Growing Eye Diseases and Disorders Is the Prime Determinant of the Market Growth
Eye care supplements are products containing vitamins and other nutrients that are useful for maintaining eye health and good vision. They improve eye health and can be used for the treatment of a number of related diseases such as cataracts, diabetic retinopathy, and glaucoma. Many people face the problem of poor vision. The primary method of improving the vision is use of dietary products extracted from both natural and synthetic sources such as plants. Antioxidants, omega fatty acids are the most widely used eye care supplements across the globe. 
Key Players  
Some of the key players in this market are
  • Biosyntrx Inc. (U.S.),
  • Nordic Naturals Inc. (U.S.),
  • Bristol-Myers Squibb Company (U.S.),
  • Healths Harmony USA Supplements LLC (U.S),
  • NUSAPURE (U.S.),
  • Vitabiotics Ltd. (U.K),
  • Bausch & Lomb Incorporated. (U.S.).
Market Dynamics
Growing Awareness and Geriatric Population Is Charging A High Market Demand
According to the Economic and Social Commission estimates for Asia and the Pacific, in 2016 about 12.4 % of the population within the region aged 60 or more and this geriatric population is projected to reach 1.3 billion by 2050. Increasing prevalence of eye diseases and chronic diseases such as diabetes, which are risk factors for eye disease is another driver of the market.
High Cost and Lack Of Healthcare Coverage And Infrastructure In Developing Regions Expected To Hamper Market Growth
The high cost of eye care supplements may restrain the market growth, especially in the developing countries.
Regional Analysis                    
America is the largest market for eye care supplements owing to an increasing demand for eye care supplements and rising prevalence of vision impairment and problems among people in the US. According to the Center of Disease Control and Prevention, nearly 14 million Americans aged 12 years and older have some form of visual impairment.
According to the World Health Organization, about 60 million European have diabetes and the prevalence of diabetes is relatively high among people over 25 years.
Europe is the second largest market for eye care supplements which will steady growth in the near future du rot the availability of cost effective treatments and prevention strategy.
The Middle East & Africa also show a steady rise in the market owing to rise in the demand for ophthalmic products and available treatment options.
In Asia Pacific, the market is expected grow at a fastest rate owing to an increasing prevalence of chronic disease such as diabetes, diabetic retinopathy and obesity.
Posted by at No comments:
Subscribe to: Posts (Atom)